Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response

Inclusion Criteria: 1. Histologically or cytologically confirmed locally advanced breast carcinoma which has not been treated with any first-line therapy and will be treated with neoadjuvant chemotherapy or neoadjuvant combined chemo-radiotherapy 2. Measurable disease by ultrasound, or MRI performed within 28 days prior to treatment 3. Eastern Co-operative Oncology Group (ECOG) Performance Status of 0 or 1 4. Life expectancy of at least 6 months 5. Patients should have the ability to understand and the willingness to sign a written informed consent document. Signed informed consent must be obtained prior to any study specific procedures Exclusion Criteria: 1. History of allergic reactions attributed to compounds of similar chemical or biologic composition 2. Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, and cardiac arrhythmia 3. Psychiatric illness/social situations that would limit compliance with study requirements 4. Any condition that is unstable or could jeopardize the safety of the patient and their compliance in the study.